Literature DB >> 22262999

Positron Emission Tomography's Utility in Esophageal Cancer Management.

Shane Hopkins1, Gary Y Yang.   

Abstract

Esophageal cancer is rising in incidence and has a poor prognosis. Positron Emission Tomography (PET) is increasingly being investigated as a tool to more discriminately manage these patients. Several studies have indicated benefits in the use of PET for staging and assessment of treatment response while others have provided contradicting results. There are many possible factors that might contribute to these results, including variability in the manner of PET administration and interpretation, timing, and study design. PET acquired after chemoradiation or chemotherapy may give important prognostic information that can guide additional management decisions. Studies have had substantial variability in the timing and manner of assessing PET for this purpose, and additional study is needed.

Entities:  

Keywords:  Positron emission tomography; esophageal cancer; neoadjuvant therapy; staging

Year:  2009        PMID: 22262999      PMCID: PMC3256486     

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  32 in total

1.  Attenuation correction of PET images with respiration-averaged CT images in PET/CT.

Authors:  Tinsu Pan; Osama Mawlawi; Sadek A Nehmeh; Yusuf E Erdi; Dershan Luo; Hui H Liu; Richard Castillo; Radhe Mohan; Zhongxing Liao; H A Macapinlac
Journal:  J Nucl Med       Date:  2005-09       Impact factor: 10.057

2.  Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.

Authors:  Marinke Westerterp; Jikke M T Omloo; Gerrit W Sloof; Maarten C C M Hulshof; Otto S Hoekstra; Hans Crezee; Ronald Boellaard; Walter L Vervenne; Fiebo J W ten Kate; Jan J B van Lanschot
Journal:  Int J Hyperthermia       Date:  2006-03       Impact factor: 3.914

3.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Authors:  W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

4.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.

Authors:  P Flamen; A Lerut; E Van Cutsem; W De Wever; M Peeters; S Stroobants; P Dupont; G Bormans; M Hiele; P De Leyn; D Van Raemdonck; W Coosemans; N Ectors; K Haustermans; L Mortelmans
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

5.  Proposed revision of the staging classification for esophageal cancer.

Authors:  R J Korst; V W Rusch; E Venkatraman; M S Bains; M E Burt; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1998-03       Impact factor: 5.209

Review 6.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 7.  PET/CT of esophageal cancer: its role in clinical management.

Authors:  John F Bruzzi; Reginald F Munden; Mylene T Truong; Edith M Marom; Bradley S Sabloff; Gregory W Gladish; Revathy B Iyer; Tin-Su Pan; Homer A Macapinlac; Jeremy J Erasmus
Journal:  Radiographics       Date:  2007 Nov-Dec       Impact factor: 5.333

8.  Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?

Authors:  James M McLoughlin; Marcovalerio Melis; Erin M Siegel; E Michelle Dean; Jill M Weber; Jeannie Chern; Melanie Elliott; Scott T Kelley; Richard C Karl
Journal:  J Am Coll Surg       Date:  2008-05       Impact factor: 6.113

9.  Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.

Authors:  Jeffrey L Port; Paul C Lee; Robert J Korst; Yaakov Liss; Danish Meherally; Paul Christos; Madhu Mazumdar; Nasser K Altorki
Journal:  Ann Thorac Surg       Date:  2007-08       Impact factor: 4.330

10.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

View more
  3 in total

1.  FDG PET imaging in the staging and management of gastric cancer.

Authors:  Shane Hopkins; Gary Y Yang
Journal:  J Gastrointest Oncol       Date:  2011-03

2.  A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma.

Authors:  Yang Ling; Jia Chen; Min Tao; Xiaoyuan Chu; Xizhi Zhang
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

3.  HtrA1 expression associated with the occurrence and development of esophageal cancer.

Authors:  Youtao Yu; Wenlong Shao; Yi Hu; Jingyan Zhang; Hao Song; Zhi-hua Zhu
Journal:  World J Surg Oncol       Date:  2012-08-30       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.